<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02417116</url>
  </required_header>
  <id_info>
    <org_study_id>TP00128</org_study_id>
    <nct_id>NCT02417116</nct_id>
  </id_info>
  <brief_title>Tear Osmolarity Clinical Utility in Dry Eye Disease</brief_title>
  <official_title>Tear Osmolarity Clinical Utility in Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TearLab Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Millions of people suffer from dry eye disease, causing symptoms such as redness, burning,
      feeling of sand or grit in the eye and light sensitivity. Dry eye disease occurs when your
      eyes do not produce enough tears or produce poor quality tears. This can happen for a number
      of reasons, including aging, hormonal changes in women and side effects of diseases or
      medications.

      It is now possible to objectively measure the degree of dry eye disease by collecting a tiny
      sample of tears from the corner of the eye and then measuring the amount of salt in the tears
      (termed osmolarity). We aim to establish the overall levels of raised and normal tear
      osmolarity in people presenting to the eye clinic with complaints of dry eye, and relate this
      to other factors such as symptoms, topical and nutritional medication and dry eye treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the efficacy of two treatment non-pharmaceutical therapies (tear
      drop alone, tear drop combined with omega 3 nutritional supplement and warm compresses) for
      dry eye reporting patients against a control (saline) over a 3 month period. A relatively new
      clinical measure (osmolarity) will be performed alongside traditional tear film volume, tear
      film stability, gland integrity and ocular surface damage measures to determine how this
      influences symptomatic complaints.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Osmolarity change</measure>
    <time_frame>3 months</time_frame>
    <description>Salt balance in tears measured with the Tearlab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tear break-up time change</measure>
    <time_frame>3 months</time_frame>
    <description>Tear stability following a blink</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal staining change</measure>
    <time_frame>3 months</time_frame>
    <description>Fluorescein dye applied to the ocular surface and observed with blue light and a yellow filter to observe staining fluorescence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meibomian gland change</measure>
    <time_frame>3 months</time_frame>
    <description>Grading of meibomian glands using Oxford scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Meniscus Height</measure>
    <time_frame>3 months</time_frame>
    <description>Height of tear meniscus along the lower lid margin observed through a slit-lamp microscope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPEED Questionnaire change</measure>
    <time_frame>3 months</time_frame>
    <description>Dry eye symptomology questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Minims Saline (Preservative Free) lubricant eye drops - daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypromellose - standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tear Supplement: Hypromellose 0.3% eye drops - daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tear Supplement 2: Hylo-Forte 0.2% Sodium Hyaluronate eye drops, Omega 3 nutrition supplement: Omega-3 tablets, Eye bag: TranquilEyes Moist Heat Lid Compresses - Daily for 90 days;</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tear supplement</intervention_name>
    <description>Application as required to improve comfort</description>
    <arm_group_label>Hypromellose - standard treatment</arm_group_label>
    <other_name>Hypermellose 0.3% eye drop</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tear supplement 2</intervention_name>
    <description>Application as required to improve comfort</description>
    <arm_group_label>Combination treatment</arm_group_label>
    <other_name>Hylo-Forte 0.2% Sodium Hyaluronate eye drop</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 3 nutrition supplement</intervention_name>
    <description>Taken each day</description>
    <arm_group_label>Combination treatment</arm_group_label>
    <other_name>Scope Ophthalmics Omega Eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eye bag</intervention_name>
    <description>Applied following microwave heating to closed eyelids for 5 minutes each day</description>
    <arm_group_label>Combination treatment</arm_group_label>
    <other_name>TranquilEyes Moist Heat Lid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Application as required to improve comfort</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Minim sodium chloride 0.9% unpreserved</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dry Eye Symptoms SPEED &gt;8

        Exclusion Criteria:

          -  Unable to participate in 90 days therapy

          -  Allergic to therapy

          -  On medication known to affect ocular surface / tear film

          -  Had ocular trauma, infection or surgery

          -  Diagnosed with a medical condition known to affect ocular surface / tear film
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Wolffsohn, BSc MBA PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Frith Opticians</name>
      <address>
        <city>Shaftesbury</city>
        <state>Dorest</state>
        <zip>SP7 8AR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Frith Opticians</name>
      <address>
        <city>Blandford</city>
        <state>Dorset</state>
        <zip>DT11 8AR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Frith Opticians</name>
      <address>
        <city>Gillingham</city>
        <state>Dorset</state>
        <zip>SP8 4AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Frith Opticians</name>
      <address>
        <city>Twickenham</city>
        <state>Middlesex</state>
        <zip>TW1 4BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black &amp; Lizars Optometrists</name>
      <address>
        <city>Ayr</city>
        <zip>KA7 1UL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black &amp; Lizars Optometrists</name>
      <address>
        <city>Glasgow</city>
        <zip>G46 6JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2015</study_first_submitted>
  <study_first_submitted_qc>April 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

